Dossier assessment
Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2021.07.15 A G-BA decision was published.
Project details
- Project no.
- A21-12
- Commission
- Commission awarded on 01.02.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Addendum to Commission A21-12
Status: Commission completed